FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007433178> ?p ?o ?g. }

• W3007433178 endingPage "3286" @default.
• W3007433178 startingPage "3280" @default.
• W3007433178 abstract "Abstract Purpose: Immune checkpoint inhibitors (ICI) are a significant advance to the treatment of advanced non–small cell lung cancer (NSCLC); however, their initiation is associated with heterogeneity in outcomes. This study aimed to develop and validate a prognostic tool of survival in patients with advanced NSCLC treated with ICIs. Experimental Design: A pretreatment prognostic model was developed and validated using clinicopathologic data. Development data consisted of patients with advanced NSCLC treated with atezolizumab from the randomised trials OAK and POPLAR (n = 751). Data from the single-arm atezolizumab trials BIRCH and FIR (n = 797) were used for external validation. Prognostic scores were categorized into low, intermediate-low, intermediate, intermediate-high, and high-risk prognostic groups. The primary outcome was overall survival (OS), with progression-free survival (PFS) secondary. Results: Pretreatment C-reactive protein (CRP) was the most predictive variable for OS. The prognostic tool was optimally defined by CRP, lactate dehydrogenase, derived neutrophil-to-lymphocyte ratio, albumin, PD-L1 expression, performance status, time since metastatic diagnosis, and metastatic site count. Prognostic groups had significantly different OS (c-statistic = 0.72), with median OS ranging from &gt;24 to 3 months for the low- to high-risk groups. Performance was maintained on validation (c = 0.76). These findings were similar for PFS, with median PFS ranging from 5 months to 1 month for the low- to high-risk groups. Benefit of atezolizumab (vs. docetaxel) was greatest in the low-risk group (&gt;3 months median OS improvement), with little benefit apparent for the highest risk group. Conclusions: A prognostic tool was developed and validated to identify patient groups with distinctly different survival following atezolizumab initiation for advanced NSCLC." @default.
• W3007433178 created "2020-03-06" @default.
• W3007433178 creator A5008197704 @default.
• W3007433178 creator A5018355869 @default.
• W3007433178 creator A5040080843 @default.
• W3007433178 creator A5060370312 @default.
• W3007433178 creator A5067594062 @default.
• W3007433178 creator A5068720728 @default.
• W3007433178 date "2020-07-01" @default.
• W3007433178 modified "2023-10-06" @default.
• W3007433178 title "Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab" @default.
• W3007433178 cites W2041352695 @default.
• W3007433178 cites W2081202263 @default.
• W3007433178 cites W2107934474 @default.
• W3007433178 cites W2123998733 @default.
• W3007433178 cites W2153294383 @default.
• W3007433178 cites W2171642892 @default.
• W3007433178 cites W2171776474 @default.
• W3007433178 cites W2293531514 @default.
• W3007433178 cites W2398917392 @default.
• W3007433178 cites W2498119267 @default.
• W3007433178 cites W2527905628 @default.
• W3007433178 cites W2567564314 @default.
• W3007433178 cites W2625684877 @default.
• W3007433178 cites W2746214449 @default.
• W3007433178 cites W2760874344 @default.
• W3007433178 cites W2763123273 @default.
• W3007433178 cites W2784283849 @default.
• W3007433178 cites W2790680615 @default.
• W3007433178 cites W2804780558 @default.
• W3007433178 cites W2807965874 @default.
• W3007433178 cites W2888038493 @default.
• W3007433178 cites W2889787933 @default.
• W3007433178 cites W2902771169 @default.
• W3007433178 cites W2936066104 @default.
• W3007433178 cites W2940307933 @default.
• W3007433178 cites W2947713025 @default.
• W3007433178 cites W2964098540 @default.
• W3007433178 cites W2967144404 @default.
• W3007433178 cites W2968530115 @default.
• W3007433178 cites W2975768638 @default.
• W3007433178 doi "https://doi.org/10.1158/1078-0432.ccr-19-2968" @default.
• W3007433178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32086341" @default.
• W3007433178 hasPublicationYear "2020" @default.
• W3007433178 type Work @default.
• W3007433178 sameAs 3007433178 @default.
• W3007433178 citedByCount "26" @default.
• W3007433178 countsByYear W30074331782020 @default.
• W3007433178 countsByYear W30074331782021 @default.
• W3007433178 countsByYear W30074331782022 @default.
• W3007433178 countsByYear W30074331782023 @default.
• W3007433178 crossrefType "journal-article" @default.
• W3007433178 hasAuthorship W3007433178A5008197704 @default.
• W3007433178 hasAuthorship W3007433178A5018355869 @default.
• W3007433178 hasAuthorship W3007433178A5040080843 @default.
• W3007433178 hasAuthorship W3007433178A5060370312 @default.
• W3007433178 hasAuthorship W3007433178A5067594062 @default.
• W3007433178 hasAuthorship W3007433178A5068720728 @default.
• W3007433178 hasBestOaLocation W30074331782 @default.
• W3007433178 hasConcept C121608353 @default.
• W3007433178 hasConcept C126322002 @default.
• W3007433178 hasConcept C143998085 @default.
• W3007433178 hasConcept C2775949291 @default.
• W3007433178 hasConcept C2776256026 @default.
• W3007433178 hasConcept C2777701055 @default.
• W3007433178 hasConcept C2780030458 @default.
• W3007433178 hasConcept C2781190966 @default.
• W3007433178 hasConcept C50382708 @default.
• W3007433178 hasConcept C71924100 @default.
• W3007433178 hasConceptScore W3007433178C121608353 @default.
• W3007433178 hasConceptScore W3007433178C126322002 @default.
• W3007433178 hasConceptScore W3007433178C143998085 @default.
• W3007433178 hasConceptScore W3007433178C2775949291 @default.
• W3007433178 hasConceptScore W3007433178C2776256026 @default.
• W3007433178 hasConceptScore W3007433178C2777701055 @default.
• W3007433178 hasConceptScore W3007433178C2780030458 @default.
• W3007433178 hasConceptScore W3007433178C2781190966 @default.
• W3007433178 hasConceptScore W3007433178C50382708 @default.
• W3007433178 hasConceptScore W3007433178C71924100 @default.
• W3007433178 hasFunder F4320320438 @default.
• W3007433178 hasIssue "13" @default.
• W3007433178 hasLocation W30074331781 @default.
• W3007433178 hasLocation W30074331782 @default.
• W3007433178 hasLocation W30074331783 @default.
• W3007433178 hasLocation W30074331784 @default.
• W3007433178 hasLocation W30074331785 @default.
• W3007433178 hasOpenAccess W3007433178 @default.
• W3007433178 hasPrimaryLocation W30074331781 @default.
• W3007433178 hasRelatedWork W2024495613 @default.
• W3007433178 hasRelatedWork W2097791366 @default.
• W3007433178 hasRelatedWork W2098897002 @default.
• W3007433178 hasRelatedWork W2484703144 @default.
• W3007433178 hasRelatedWork W2516175431 @default.
• W3007433178 hasRelatedWork W2590036280 @default.
• W3007433178 hasRelatedWork W3101357651 @default.
• W3007433178 hasRelatedWork W3125772867 @default.
• W3007433178 hasRelatedWork W4229031678 @default.
• W3007433178 hasRelatedWork W3118988410 @default.

• next